Another of the UK's most promising biotech companies has become the target of big pharma, with GlaxoSmithKline entering into an agreement to acquire privately held Domantis for #8356;230 M (US$454 M) in cash. This feature outlines Domantis' domain antibody (dAb) technology, which it is developing for the treatment of various diseases, its early investment history – most significantly that from the Australian biotech Peptech, and its partnering history. It also discusses how the acquisition of Domantis fits the pattern of a number of deals done by big pharma companies in 2006 that aimed to bring their antibody therapeutics capabilities rapidly up to speed by purchasing entire companies, rather than just licensing individual products and technologies.